Infant Bacterial Therapeutics AB Class B IBT B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 33.20
- Day Range
- SEK 32.70–33.80
- 52-Week Range
- SEK 21.70–135.00
- Bid/Ask
- SEK 32.70 / SEK 33.20
- Market Cap
- SEK 445.90 Mil
- Volume/Avg
- 21,005 / 93,840
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.ibtherapeutics.com
Comparables
Valuation
|
Metric
|
IBT B
|
EGTX
|
CAMX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 112.42 |
Price/Book Value | 1.88 | 3.22 | 12.82 |
Price/Sales | — | 17.80 | 23.46 |
Price/Cash Flow | — | — | 82.65 |
Price/Earnings
IBT B
EGTX
CAMX
Financial Strength
|
Metric
|
IBT B
|
EGTX
|
CAMX
|
|---|---|---|---|
Quick Ratio | 4.80 | 1.55 | 7.11 |
Current Ratio | 4.80 | 1.56 | 7.41 |
Interest Coverage | — | −22.42 | 200.63 |
Quick Ratio
IBT B
EGTX
CAMX
Profitability
|
Metric
|
IBT B
|
EGTX
|
CAMX
|
|---|---|---|---|
Return on Assets (Normalized) | −40.16% | −49.14% | 14.11% |
Return on Equity (Normalized) | −47.23% | −65.52% | 17.07% |
Return on Invested Capital (Normalized) | −51.10% | −56.41% | 14.74% |
Return on Assets
IBT B
EGTX
CAMX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qfrwktpqf | Nlcm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jxntxzwb | Pxtjdg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sfnjgryy | Pwqqgt | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Crzvnwxf | Rvgps | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Sdghgtgrl | Mrd | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Msqjzsbn | Kynhf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wstlxwyl | Cfgc | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Jxwzslsyy | Fdbl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kwqjcjfm | Cdnpcs | $13.4 Bil | |||
| Incyte Corp
INCY
| Rwfdcqlj | Zwbsqtg | $12.7 Bil |
United States